Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: ACLS THER

Market Cap 617M 533M 490M 461M 866M 58.26B 873M 5.8B 2.26B 28.59B 2.32B 2.27B 98.91B P/E 2026 *
-6.81x
P/E 2027 * -5.55x
Enterprise Value 482M 416M 382M 360M 676M 45.46B 681M 4.53B 1.76B 22.31B 1.81B 1.77B 77.19B EV / Sales 2026 *
84.3x
EV / Sales 2027 * 91.9x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 17/01/2024
President 67 18/11/2024
Director of Finance/CFO 39 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2023
Chairman 60 01/06/2019
Director/Board Member 50 01/09/2014
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%+0.77%+65.31%+117.05% 56.24B
+0.04%+1.20%+47.67%+36.75% 43.76B
+3.04%+7.05%-12.15%-18.06% 23.32B
+3.07%+7.15%-1.82%+392.25% 21.34B
+3.01%+2.94%+24.02%-34.00% 15.75B
+0.99%+1.87%+13.67%-38.81% 15.6B
+0.65%-0.27%+26.80%+174.70% 13.18B
+2.63%+4.87%+20.72% - 12.01B
+1.92%+2.43%+112.68%+232.59% 11.87B
Average +1.75%+3.15%+32.99%+107.81% 23.68B
Weighted average by Cap. +1.31%+2.96%+37.40%+99.79%

Financials

2026 *2027 *
Net sales 5.71M 4.93M 4.53M 4.26M 8.01M 539M 8.08M 53.69M 20.9M 265M 21.44M 20.98M 915M 5.36M 4.62M 4.25M 4M 7.52M 506M 7.58M 50.37M 19.61M 248M 20.11M 19.68M 859M
Net income -84.78M -73.14M -67.25M -63.29M -119M -8B -120M -797M -310M -3.93B -318M -311M -13.58B -103M -88.44M -81.31M -76.53M -144M -9.67B -145M -964M -375M -4.75B -385M -377M -16.43B
Net Debt -136M -117M -108M -101M -190M -12.8B -192M -1.27B -496M -6.28B -509M -498M -21.73B -125M -108M -99.06M -93.24M -175M -11.79B -177M -1.17B -457M -5.79B -469M -459M -20.01B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!